|
|
Novel Small-molecule TNF-a Modulators as Chemoprotective Agents
|
1R43CA141749-01
|
$154,852
|
$154,852
|
SHAW, JIAJIU
|
21ST CENTURY THERAPEUTICS, INC.
|
|
|
Targeted Prodrug Chemotherapy for Prostate Cancer
|
1R43CA139677-01A1
|
$159,988
|
$159,988
|
Wu, Jenny
|
ACADUCEUS PHARMACEUTICS, INC.
|
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
4R44CA124032-02
|
$1,473,388
|
$1,473,388
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
|
Proton-coupled folate/antifolate transport
|
2R01CA082621-11
|
$526,718
|
$526,718
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
5P30CA013330-37
|
$3,927,232
|
$314,179
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
New Approaches to Prevent or Treat Breast Cancer Metastases
|
5R21CA129470-03
|
$186,750
|
$93,375
|
GRAVEKAMP, CLAUDIA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
H/D Exchange Coupled to MS to Study Drug-Induced Change in Microtuble Structure
|
5R01CA124898-03
|
$315,400
|
$315,400
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Chemical Modulation of Orphan Nuclear Receptor Function
|
1R01CA127231-01A2
|
$275,560
|
$275,560
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Proteomic analysis of head & neck squamous cell cancer
|
5R33CA103547-05
|
$695,192
|
$347,596
|
PRYSTOWSKY, MICHAEL
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Radiation Therapy Oncology Group
|
2U10CA021661-33
|
$12,534,580
|
$7,771,440
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-22S1
|
$26,578
|
$8,239
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
5U10CA037422-22
|
$1,683,081
|
$521,755
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
QUALITY RESEARCH IN RADIATION ONCOLOGY: ACR PCS
|
5R01CA065435-11
|
$564,543
|
$197,590
|
WILSON, JESSE
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ
|
1R43CA137737-01
|
$139,945
|
$139,945
|
Zwick, Michael
|
ANDROBIOSYS, INC.
|
|
|
Optimization of dipeptide-linked benzimidazole topoisomerase 1 poisons
|
1R41CA132413-01A2
|
$260,988
|
$260,988
|
Beeson, Craig
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
|
Targeted Ceramic Nanovectors for Simultaneous Therapy and Imaging of Cancer
|
5R21CA133618-02
|
$129,423
|
$64,712
|
DEY, SANDWIP
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Microfluidics-Based Platform for Screening Combinatorial Drug Treatments
|
5R21CA131891-02
|
$163,887
|
$163,887
|
Rege, Kaushal
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Drug Delivery Carriers Targeted to Breast Tumor by Fusion Phage Proteins
|
5R01CA125063-03
|
$380,792
|
$380,792
|
PETRENKO, VALERY
|
AUBURN UNIVERSITY AT AUBURN
|
|
|
Novel human anti-uPAR antibodies for the treatment of pancreatic cancer
|
1R43CA137884-01A1
|
$158,025
|
$79,013
|
FAN, XIAOMIN
|
AVANTGEN, INC.
|
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-20
|
$521,201
|
$229,328
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
|
NSABP Participating Sites
|
5U10CA118735-04
|
$67,765
|
$42,014
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Proteosome Inhibition Therapy for Hematologic Malignancy
|
5K23CA113775-04
|
$134,015
|
$134,015
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational Research in Breast Cancer
|
5P50CA058183-15
|
$2,300,000
|
$1,150,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Pediatric Clinical Oncology Research Training Program
|
3K12CA090433-08S1
|
$77,845
|
$15,569
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Pediatric Clinical Oncology Research Training Program
|
5K12CA090433-08
|
$750,727
|
$150,145
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Development of an HSV-2 based oncolytic virus
|
1R01CA132792-01A1
|
$202,620
|
$101,310
|
ZHANG, XIAOLIU
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Improving the Efficacy of Dendritic Cell Vaccines
|
3P01CA084512-07S1
|
$200,000
|
$60,000
|
Banchereau, Jacques
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-26
|
$430,954
|
$181,001
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
DF/HCC Kidney Cancer SPORE
|
2P50CA101942-06A1
|
$2,300,000
|
$276,000
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-11
|
$130,866
|
$130,866
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Optimizing localized therapy for primary liver cancer: a clinical trial and model
|
1K23CA139005-01A1
|
$169,020
|
$169,020
|
Miksad, Rebecca
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
|
5R01CA129339-02
|
$352,750
|
$352,750
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Circulating Tumor Cells in Non-Small Cell Lung Cancer
|
5R01CA125653-03
|
$337,278
|
$337,278
|
Nieva, Jorge
|
BILLINGS CLINIC FOUNDATION
|
|
|
Evaluation of DNA Cross-Linking by Aziridinomitosenes
|
2R15CA113464-02
|
$218,815
|
$218,815
|
Warner, Don
|
BOISE STATE UNIVERSITY
|
|
|
Cyclic AMP-mediated apoptosis in lymphoid malignancies
|
5R01CA106705-05
|
$241,199
|
$241,199
|
LERNER, ADAM
|
BOSTON MEDICAL CENTER
|
|
|
Cancer Control in Older Adults
|
5K05CA092395-09
|
$148,568
|
$148,568
|
SILLIMAN, REBECCA
|
BOSTON MEDICAL CENTER
|
|
|
Long-term Survivorship in Older Women with Early Stage Breast Cancer
|
5R01CA093772-06
|
$1,245,685
|
$622,843
|
SILLIMAN, REBECCA
|
BOSTON MEDICAL CENTER
|
|
|
Inducing Chromosomal Damage Responses in Pancreatic Cancer
|
1R21CA133654-01A2
|
$178,750
|
$178,750
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Ras Oncoprotein-Targeted Therapy for Cancer
|
3R01CA112102-05S1
|
$56,604
|
$56,604
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Ras Oncoprotein-Targeted Therapy for Cancer
|
5R01CA112102-05
|
$302,435
|
$302,435
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Modification of tamoxifen effectiveness by gene polymorphisms and other drugs
|
5R01CA118708-04
|
$234,985
|
$117,493
|
LASH, TIMOTHY
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
The fuel sensing enzyme AMPK in the pathogenesis of prostate cancer
|
5R01CA118918-04
|
$224,058
|
$224,058
|
Luo, Zhijun
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Novel vitamin D analog for kidney cancer
|
5R21CA127629-02
|
$219,375
|
$219,375
|
RAY, RAHUL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Heat shock proteins in signaling and cancer
|
2R01CA081244-11A2
|
$355,597
|
$71,119
|
SHERMAN, MICHAEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Effects of mTOR inhibitors on multiple myeloma tumors
|
5K01CA111623-05
|
$149,580
|
$149,580
|
Frost, Patrick
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Use of CCI-779 in multiple myeloma
|
5R21CA121464-02
|
$319,950
|
$319,950
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
|
3P50CA105009-05S1
|
$1,193,174
|
$238,635
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Mouse Models for Human Cancer
|
2U01CA084301-11
|
$664,955
|
$166,239
|
KUCHERLAPATI, RAJU
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
SPORE in Skin Cancer
|
5P50CA093683-07
|
$2,300,000
|
$460,000
|
KUPPER, THOMAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Biomarkers and Therapeutic Targets in Pancreatic Cancer
|
5R01CA114103-05
|
$287,037
|
$114,815
|
WHANG, EDWARD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Total relevant funding to Chemotherapy for this search: $528,665,822
|
